rpl-36 Antibody

What is RPL36 and what is its primary function in cells?

RPL36 (also known as large ribosomal subunit protein eL36 or 60S ribosomal protein L36) is a component of the large ribosomal subunit, which forms part of the ribosome—the cellular machinery responsible for protein synthesis. The ribosome is a large ribonucleoprotein complex that translates mRNA into proteins, with RPL36 playing a structural and functional role in this process . Beyond its canonical role in translation, RPL36 has been implicated in tumor suppression, as demonstrated in zebrafish models of pancreatic cancer where RPL36 haploinsufficiency accelerated KRAS-G12V-induced tumor progression . This suggests that RPL36 has additional functions beyond protein synthesis that may be critical in maintaining cellular homeostasis and preventing malignant transformation.

What types of RPL36 antibodies are currently available for research?

Currently, researchers have access to several types of polyclonal antibodies against RPL36. For instance, rabbit polyclonal antibodies such as ab196734 and ab138032 are commercially available for detecting human RPL36 in various experimental contexts . These antibodies have been raised against synthetic peptides corresponding to regions within human RPL36. According to validated specifications, these antibodies demonstrate compatibility with different experimental applications: ab196734 is suitable for immunohistochemistry-paraffin (IHC-P) and immunocytochemistry/immunofluorescence (ICC/IF), while ab138032 has been validated for western blotting (WB) . Each antibody has specific reactivity profiles, with both showing confirmed reactivity with human samples, making them valuable tools for investigating RPL36 expression and localization in human cell lines and tissues.

How is alt-RPL36 different from canonical RPL36?

Alt-RPL36 is a protein translated from an alternative reading frame of the RPL36 transcript variant 2, creating a distinct protein product with completely different amino acid sequence despite sharing the same mRNA . While canonical RPL36 is part of the ribosomal machinery, alt-RPL36 has been found to play a regulatory role in the PI3K-AKT-mTOR signaling pathway. Structurally, alt-RPL36 is longer than RPL36 and completely encompasses its coding sequence but is translated in the -1 reading frame relative to RPL36 . This results in two proteins with entirely different amino acid sequences despite being encoded by overlapping genomic regions. Alt-RPL36 has been detected in multiple human cell lines, including HEK 293T, HT1080, and MOLT4 cells, suggesting widespread expression . Unlike canonical RPL36, which is primarily associated with ribosomes, alt-RPL36 partially localizes to the endoplasmic reticulum, as demonstrated through both immunostaining of endogenously expressed tagged protein and genetic code expansion-mediated labeling techniques .

What are the optimal protocols for using RPL36 antibodies in Western blotting?

For Western blotting applications with RPL36 antibodies, researchers should follow a systematic approach that accounts for the protein's characteristics and expression levels. Based on available literature and technical specifications, the following protocol is recommended: Begin with sample preparation by lysing cells in RIPA buffer supplemented with protease inhibitors, followed by protein quantification using BCA or Bradford assay . Separate 10-20 μg of total protein on a 12-15% SDS-PAGE gel, as RPL36 is a relatively small protein (approximately 12 kDa). After electrophoresis, transfer proteins to a PVDF membrane using a semi-dry or wet transfer system (25V for 1.5 hours) . For blocking, use 5% non-fat milk in TBST for 1 hour at room temperature. Incubate the membrane with anti-RPL36 antibody (such as ab138032) at a 1:1000-1:2000 dilution in blocking buffer overnight at 4°C . Following primary antibody incubation, wash the membrane 3-4 times with TBST before adding HRP-conjugated secondary antibody (anti-rabbit) at 1:5000-1:10000 dilution for 1 hour at room temperature. After washing, visualize the protein using enhanced chemiluminescence detection. For verification of specificity, consider running parallel samples with RPL36 knockdown controls or peptide competition assays.

How can researchers effectively use RPL36 antibodies for immunohistochemistry and immunofluorescence?

For immunohistochemistry (IHC) applications with RPL36 antibodies, researchers should begin with appropriate tissue preparation and antigen retrieval. For paraffin-embedded samples, heat-mediated antigen retrieval has been validated for RPL36 detection . Based on published protocols, deparaffinize sections using histoclear and rehydrate through a graded alcohol series. Perform heat-mediated antigen retrieval using citrate buffer (pH 6.0) or other validated retrieval solutions . After blocking endogenous peroxidase activity with 3% H₂O₂, incubate sections with blocking buffer (5-10% normal serum in PBS with 0.1% Triton X-100) for 1 hour at room temperature. Apply primary anti-RPL36 antibody (such as ab196734) at a 1:50 dilution in blocking buffer and incubate overnight at 4°C . For immunohistochemistry, use appropriate HRP-conjugated secondary antibodies followed by DAB development. For immunofluorescence applications, use A549 cells or other human cell lines grown on coverslips, fix with 4% paraformaldehyde, permeabilize with 0.1% Triton X-100, and block with 5% BSA. Apply RPL36 antibody at a 1:100 dilution overnight at 4°C, followed by fluorophore-conjugated secondary antibodies . Include appropriate negative controls (primary antibody omission) and specificity controls (peptide competition) to validate staining patterns.

What controls should be included in experiments using RPL36 antibodies?

Rigorous experimental design with RPL36 antibodies requires comprehensive controls to ensure specificity and reliability of results. At minimum, researchers should include: (1) Negative controls: samples processed identically but without primary antibody to identify nonspecific binding of secondary antibodies; (2) Peptide competition assays: pre-incubating the antibody with excess immunizing peptide to confirm binding specificity, as demonstrated in the immunohistochemical analysis of human prostate carcinoma tissue and immunofluorescent analysis of A549 cells using ab196734 ; (3) Knockdown/knockout controls: using siRNA, shRNA, or CRISPR-Cas9 to reduce or eliminate RPL36 expression, verifying antibody specificity against endogenous protein; (4) Positive controls: samples known to express RPL36 at detectable levels, such as HEK 293T cells for Western blotting or human prostate tissue for IHC . For advanced applications, researchers can include isotype controls (non-specific antibodies of the same isotype) and cross-reactivity controls (testing against closely related ribosomal proteins). For studies examining both canonical RPL36 and alt-RPL36, researchers should use constructs that express only one of these proteins to distinguish their patterns and confirm antibody specificity for each protein variant .

How can researchers investigate the relationship between RPL36 and cancer progression?

To investigate RPL36's potential tumor suppressor function, researchers should implement a multi-faceted approach combining in vitro, in vivo, and clinical samples. Based on the zebrafish pancreatic cancer model studies, researchers can begin by examining RPL36 expression levels across normal pancreatic tissue, precancerous lesions (PanINs), and invasive pancreatic ductal adenocarcinoma (PDAC) using immunohistochemistry with validated anti-RPL36 antibodies (dilution 1:50) . For mechanistic studies, establish RPL36 knockdown or knockout cell lines using RNA interference or CRISPR-Cas9 genome editing in pancreatic epithelial and cancer cell lines. Assess cellular phenotypes including proliferation rate, colony formation, migration, invasion, and response to therapy. For in vivo studies, researchers can adapt the zebrafish model (ptf1a:GAL4-VP16;UAS:GFP-KRAS G12V) with RPL36 haploinsufficiency or employ similar genetic strategies in mouse models . Track tumor progression through both imaging techniques and survival analysis. To translate findings to human disease, analyze RPL36 expression in patient-derived xenografts and clinical specimen cohorts across cancer stages, correlating expression levels with patient outcomes and molecular subtypes. Integrative genomic and proteomic analyses can further identify RPL36-associated gene expression networks and potential interaction partners that might contribute to its tumor suppressor function.

What methods can be used to study the phosphorylation of alt-RPL36?

To investigate alt-RPL36 phosphorylation, researchers should employ multiple complementary approaches targeting the four identified phosphoserine residues (S19, S22, S140, and S142) . Begin with immunoprecipitation of tagged alt-RPL36 from cell lysates using anti-FLAG or appropriate epitope tag antibodies, followed by phosphoprotein analysis through Phos-tag SDS-PAGE combined with western blotting. This approach has successfully distinguished between differently phosphorylated forms of alt-RPL36 . For site-specific analysis, implement site-directed mutagenesis to generate serine-to-alanine mutants (S19A, S22A, S140A, S142A, and combinations) to prevent phosphorylation at specific sites. Express these constructs in relevant cell lines and analyze their phosphorylation states and functional consequences. For phosphorylation dynamics, treat cells with phosphatase inhibitors (calyculin A, okadaic acid) or stimulate with growth factors/stress conditions to analyze changes in phosphorylation patterns. Mass spectrometry represents the gold standard for phosphosite identification and quantification; perform LC-MS/MS on immunopurified and digested alt-RPL36 to confirm phosphorylation sites and potentially discover additional modifications . For functional implications, compare the subcellular localization, protein interactions, and signaling pathway effects of wild-type alt-RPL36 versus phospho-deficient mutants using microscopy, co-immunoprecipitation, and pathway analysis techniques.

How can RPL36-FLAG be utilized in ribosome ubiquitination studies?

RPL36-FLAG has proven valuable for studying ribosome ubiquitination during development and translation stress conditions. Researchers can employ the following methodology: Generate transgenic models (such as zebrafish) expressing RPL36-FLAG under endogenous or appropriate promoters to maintain physiological expression levels . For ribosome isolation, prepare embryo or cell lysates under conditions that preserve ubiquitination (including deubiquitinase inhibitors like N-ethylmaleimide). Perform FLAG immunoprecipitation to isolate ribosomes and associated factors, with option to include high-salt wash steps (500 mM NaCl) to remove loosely associated proteins while retaining core ribosomal components and their modifications . Analyze ubiquitination patterns by western blotting using anti-ubiquitin antibodies. To study specific stress responses, treat embryos or cells with translation inhibitors at varying concentrations (for example, cycloheximide at 80-320 μg/mL to induce optimal collision-dependent ubiquitination, or harringtonine to induce 80S ribosome stalling) . For targeted analysis of specific ribosomal protein ubiquitination, complement FLAG-IP with immunoblotting using antibodies against candidate ubiquitinated proteins (such as Rps10/eS10 or Rps3/uS3). To identify ubiquitination sites, combine immunoprecipitation with mass spectrometry or employ site-directed mutagenesis of candidate lysine residues followed by functional studies .

How can researchers address non-specific binding with RPL36 antibodies?

Non-specific binding is a common challenge when working with antibodies against ribosomal proteins like RPL36, which share structural similarities with other ribosomal components. To mitigate this issue, researchers should first optimize blocking conditions by testing different blocking agents (5% BSA, 5% non-fat milk, commercial blocking buffers) and increasing blocking time to 2 hours at room temperature. Antibody dilution optimization is critical; perform a titration series (1:50, 1:100, 1:500, 1:1000, etc.) to determine the optimal concentration that maximizes specific signal while minimizing background . For Western blotting applications, extend washing steps (5-6 washes of 10 minutes each) with TBST containing 0.1-0.3% Tween-20. When performing immunohistochemistry or immunofluorescence, include an additional preabsorption step with tissues or cells known not to express RPL36, or use peptide competition controls with synthetic RPL36 peptides, as demonstrated in immunofluorescence analyses of A549 cells with ab196734 . For more stringent specificity, employ a second RPL36 antibody recognizing a different epitope to confirm staining patterns. Consider using monoclonal antibodies if available, as they typically offer higher specificity than polyclonal antibodies. Finally, validate results using genetic approaches (siRNA knockdown, CRISPR knockout) to confirm that the detected signal decreases proportionally to RPL36 reduction.

How should researchers interpret different banding patterns in Western blots for RPL36 and alt-RPL36?

When analyzing Western blots for RPL36 and its alternative reading frame product (alt-RPL36), researchers must carefully interpret banding patterns based on expected molecular weights and potential post-translational modifications. Canonical RPL36 appears as a single band at approximately 12 kDa, while alt-RPL36 typically displays two distinct bands: a major lower-mobility band and a fainter higher-mobility band . The presence of multiple bands for alt-RPL36 has been demonstrated to result from phosphorylation, as treatment with nonspecific phosphatase eliminates the upper band . When interpreting these patterns, researchers should consider: (1) Molecular weight markers must be carefully assessed, as small differences in migration can be significant for these proteins; (2) Different electrophoresis conditions (gel percentage, running buffer, temperature) can affect migration patterns; (3) For alt-RPL36, expect to see up to four bands corresponding to different phosphorylation states when using Phos-tag SDS-PAGE, with the bottom band representing unphosphorylated alt-RPL36 ; (4) When analyzing phosphorylation-deficient mutants (S19A, S22A), researchers should observe specific band pattern changes—S19A mutation abolishes the second band, while S22A mutation eliminates both the first and second bands, suggesting interdependence of these phosphorylation events . To definitively distinguish between canonical RPL36 and alt-RPL36, use epitope-tagged constructs and antibodies specific to these tags rather than relying solely on anti-RPL36 antibodies.

What are the key considerations when analyzing RPL36 expression in tissue samples?

When analyzing RPL36 expression in tissue samples, researchers must account for several critical factors to ensure accurate interpretation. First, consider tissue heterogeneity and select appropriate controls: compare RPL36 expression in target tissues with matched normal tissues from the same patient when possible, as demonstrated in studies of pancreatic cancer progression . Employ standardized scoring systems for immunohistochemistry (H-score, Allred score) that account for both staining intensity and percentage of positive cells to quantify RPL36 expression objectively. Be aware of the subcellular localization pattern expected for RPL36 (primarily cytoplasmic with nucleolar enrichment due to its ribosomal nature), and any alterations in this pattern may indicate pathological changes. For pancreatic cancer studies specifically, analyze RPL36 expression across the spectrum of disease progression (normal pancreas, PanIN lesions of increasing grade, and invasive carcinoma) to capture dynamic changes . Consider the relationship between RPL36 expression and clinical parameters (tumor stage, grade, patient survival) through appropriate statistical analyses. Finally, account for potential technical variables that may affect staining outcomes: fixation time, antigen retrieval methods, and batch effects. To ensure reproducibility, process all comparative samples simultaneously using the same reagent lots and standardized protocols as described in published RPL36 immunohistochemistry methods (heat-mediated antigen retrieval, 1:50 antibody dilution) .

How might dual targeting of RPL36 and alt-RPL36 be leveraged in cancer research?

The discovery that RPL36 and alt-RPL36 are translated from the same genomic locus but serve different cellular functions presents a unique opportunity for cancer research . Future investigations could develop dual-targeting strategies that simultaneously modulate both proteins to maximize therapeutic effects. Researchers should design studies to characterize the relationship between canonical RPL36's tumor suppressor function in pancreatic cancer and alt-RPL36's role in regulating the PI3K-AKT-mTOR pathway, which is frequently dysregulated in cancer . Targeted approaches could include development of dual-function antisense oligonucleotides or siRNAs that affect both reading frames, combined with selective rescue of either RPL36 or alt-RPL36 to dissect their individual contributions to malignant phenotypes. Single-cell transcriptomics and proteomics could reveal whether the expression ratio between RPL36 and alt-RPL36 varies across cancer types and stages, potentially identifying cancers most susceptible to dual-targeting approaches. For translational applications, researchers should investigate whether the balance between RPL36 and alt-RPL36 correlates with therapeutic response, resistance mechanisms, or patient prognosis. Additionally, since alt-RPL36 affects the PI3K-AKT-mTOR pathway, combination therapies coupling PI3K/mTOR inhibitors with approaches that modulate RPL36 levels could be tested in preclinical models to determine potential synergistic effects across different cancer types.

What role might RPL36 phosphorylation play in regulating its function?

While current research has extensively characterized the phosphorylation of alt-RPL36 , the phosphorylation status and functional implications for canonical RPL36 remain largely unexplored. Future studies should investigate whether RPL36 undergoes phosphorylation similar to other ribosomal proteins, and how this might regulate its ribosomal and extra-ribosomal functions. Researchers could employ phosphoproteomic approaches combining ribosome isolation techniques (such as RPL36-FLAG immunoprecipitation) with mass spectrometry to identify potential phosphorylation sites on RPL36 . Once identified, site-directed mutagenesis could generate phospho-mimetic (serine/threonine to aspartate/glutamate) and phospho-deficient (serine/threonine to alanine) mutants to investigate functional consequences. Critical questions to address include whether phosphorylation of RPL36 affects its incorporation into ribosomes, influences translation efficiency of specific mRNA subsets, or modulates its tumor suppressor function. Researchers should also investigate the kinases and phosphatases responsible for regulating RPL36 phosphorylation under normal conditions and during cellular stress or malignant transformation. The interdependence of phosphorylation events observed with alt-RPL36 (where phosphorylation of S22 is required for S19 phosphorylation) raises the possibility that similar hierarchical modification patterns might exist for canonical RPL36, potentially creating complex regulatory networks that fine-tune ribosome function in response to cellular conditions.

How can emerging technologies improve our understanding of RPL36 in ribosome quality control?

The use of RPL36-FLAG in studying ribosome ubiquitination during zebrafish development provides a foundation for applying emerging technologies to better understand RPL36's role in ribosome quality control . Future research should leverage advanced ribosome profiling techniques coupled with ubiquitination site mapping to comprehensively characterize how RPL36 and nearby ribosomal proteins participate in translation surveillance mechanisms. Researchers can apply ribosome profiling with selective ribosome precipitation (using RPL36-FLAG) to identify specific mRNAs associated with ubiquitinated ribosomes during different types of translation stress (collisions, stalling, premature termination) . This approach could reveal whether certain mRNA features or sequence elements are enriched in ubiquitination-prone ribosomes. Cryo-electron microscopy of purified ubiquitinated ribosomes could provide structural insights into how ubiquitination of specific sites affects ribosome conformation and function. For real-time monitoring of translation quality control, researchers could develop fluorescent biosensors based on RPL36 to visualize ribosome ubiquitination dynamics in living cells. Genetic screens (CRISPR, haploid cell screens) using RPL36 ubiquitination as a readout could identify novel factors involved in ribosome quality control. Finally, single-molecule techniques tracking individual ribosomes during translation could determine how RPL36 modifications affect translation elongation rates, ribosome pausing, or recycling, providing mechanistic insights into how ribosome quality control maintains proteostasis and prevents diseases associated with proteotoxic stress.